Position in ZYME
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,944,579
+$391,453 QoQ
Shares Held
77,659
+31.7% QoQ
Ownership
0.106%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FRANKLIN RESOURCES INC holds $7,057,408,835 across 166 Biotechnology names. ZYME ranks #102 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,722,071 | $2,103,180,930 | |
| 2 | ASND |
Ascendis Pharma A/S
|
2,051,948 | $469,342,063 | |
| 3 | INSM |
INSMED Inc
|
2,617,251 | $427,972,880 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,958,940 | $370,337,604 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
551,132 | $246,102,477 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
2,438,925 | $181,114,568 | |
| 7 | ARGX |
Argenx SE
|
233,493 | $170,508,261 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
470,390 | $155,637,935 |
All Filings in ZYME
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,944,579 | 77,659 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $1,553,126 | 58,987 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $577,661 | 33,821 | Shares | Defined | 2025-11-13 | |
| 2025-03-31 | $383,024 | 32,160 | Shares | Defined | 2025-05-13 | |
| 2024-03-31 | $1,204,096 | 114,458 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $459,050 | 44,182 | Shares | Defined | 2024-02-09 | |
| 2023-09-30 | $271,915 | 42,889 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $217,105 | 25,128 | Shares | Defined | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||